Marks designated
®
and
™
are owned by Shire or an affi liated company.
©2016 Shire US Inc. Lexington, MA 02421 S12040 07/16
NIICE TO
Xiidra improved patient-reported symptoms of eye dryness and improved signs
of inferior corneal staining. So help your patients get to know Xiidra.
Check it out at Xiidra-ECP.com
Four randomized, double-masked, 12-week trials evaluated the effi cacy and safety of Xiidra versus
vehicle as assessed by improvement in the signs (measured by Inferior Corneal Staining Score) and/or
symptoms (measured by Eye Dryness Score) of Dry Eye Disease (N=2133).
The safety of lifi tegrast was evaluated in 5 clinical studies. 1401 patients received at least one dose
of lifi tegrast (1287 of which received Xiidra). The most common adverse reactions (5-25%) were
instillation site irritation, dysgeusia, and reduced visual acuity.
